Cancer patients receiving chemotherapy face roughly double the risk of being hospitalized if they catch COVID-19, according to a large National Cancer Institute study, though the picture is more nuanced than that single number suggests. Some research has found no significant link between recent chemotherapy and severe COVID outcomes, and the gap has narrowed as vaccines and treatments have improved. What hasn’t changed is that chemotherapy weakens parts of the immune system in ways that make infections harder to fight and vaccines less effective. For anyone on chemo or caring for someone who is, there are specific, practical things worth understanding about risk, vaccination timing, drug interactions, and what to do after a positive test.
How Much Does Chemotherapy Raise COVID Risk?
The clearest signal comes from the NCI’s NCCAPS study, which tracked cancer patients across dozens of U.S. sites. In that analysis, patients who had received chemotherapy were about twice as likely to be hospitalized with COVID compared to cancer patients who hadn’t had chemo recently.1JAMA Oncology. Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) – Section: Results Other risk factors in that study included a history of stroke, atrial fibrillation, or blood clots in the lungs.
But other studies have reached different conclusions. A Journal of Clinical Oncology analysis found that cytotoxic chemotherapy was not significantly associated with severe or critical COVID events.2PubMed Central. Chemotherapy and COVID-19 Outcomes in Patients With Cancer – Section: Results A separate study published in Nature Cancer found no impact of recent systemic anti-cancer therapy on COVID outcomes, and its authors explicitly supported continuing cancer care during pandemic surges.3Nature Cancer. Outcomes of COVID-19 and risk factors in patients with cancer – Section: Main These differing results likely reflect differences in the patient populations studied, the specific treatments involved, and the time period of enrollment. The NCCAPS study was large and captured a broad population, but the other studies included younger patients or different mixes of cancer types.
The honest takeaway is that chemotherapy probably does raise the risk of a worse COVID outcome, but not every patient on chemo faces the same level of added danger. The type of cancer, specific drugs used, and your overall health all factor in. What every oncologist agrees on is that a suppressed immune system makes infections harder to clear, and chemo does suppress parts of the immune system, particularly the white blood cells responsible for fighting off invaders.
Why Chemotherapy Makes Infections Trickier
Chemotherapy targets rapidly dividing cells, which includes cancer cells but also immune cells. The result is often neutropenia, a drop in a specific type of white blood cell. Neutrophils are frontline defenders against bacteria and viruses, and when their numbers fall, the body struggles to mount an effective response to any infection, including SARS-CoV-2.4Journal of Infection and Public Health. Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapy Certain chemotherapy agents can also cause direct lung toxicity, which means the respiratory system may already be compromised before a respiratory virus enters the picture. This overlap between chemo-related lung effects and COVID pneumonia is one reason clinicians watch these patients closely.
Vaccines Work, but Not as Well
If you’re on chemotherapy, COVID vaccines still work for you, just not as strongly or as quickly as they do for people with healthy immune systems. A meta-analysis of solid cancer patients found that immune responses to COVID vaccines were consistently weaker compared to healthy controls after all three doses, with the biggest gap appearing after the first dose and gradually narrowing with subsequent shots.5PubMed Central. Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis – Section: Results
A systematic review put more specific numbers on this. After a first dose, only about 37% of cancer patients developed detectable antibodies, compared with roughly 74% of healthy controls. After a full vaccination course, the gap closed but didn’t disappear: about 78% of cancer patients seroconverted versus nearly 100% of healthy people.6Frontiers in Oncology. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review – Section: Results Patients with blood cancers fared worse than those with solid tumors, achieving seroconversion about 73% of the time even after full vaccination.
A closer look at what’s happening at the cellular level is revealing. One study found that while cancer patients on chemo could produce antibodies at similar overall levels to healthy people for some measures, their antibodies were less effective at actually neutralizing the virus, and these antibodies faded faster over four to six months. Booster doses helped, but the gains were smaller for patients on chemo. The researchers also found signs of impaired immune memory in chemo recipients, suggesting their B cells had trouble maturing into the long-lasting memory cells that provide durable protection.7Frontiers in Immunology. Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors – Section: Results
Timing Your Vaccine Around Chemo Cycles
Because chemo suppresses the immune system in predictable waves, timing a vaccination can make a meaningful difference. The general recommendation is to get vaccinated before starting chemotherapy if possible, or between cycles and away from the nadir phase, which is when white blood cell counts hit their lowest point, typically a week or two after an infusion.8PubMed Central. COVID-19 Vaccination in Cancer Patients: A Review Article – Section: Abstract Your oncologist can help pinpoint the best window based on your specific regimen. The goal is to give your immune system the best possible shot at responding to the vaccine, which means vaccinating when your white blood cell counts are recovering rather than bottoming out.
Vaccine Safety on Chemo
One concern many patients have is whether a COVID vaccine will cause worse side effects when layered on top of chemotherapy. The reassuring answer from multiple studies is that it doesn’t. In a study of actively treated cancer patients receiving the Pfizer-BioNTech vaccine, the most common side effects were local pain at the injection site, weakness, muscle aches, and headache, and no severe or life-threatening reactions were reported.9JNCI: Journal of the National Cancer Institute. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients – Section: Results A separate study of patients on chemo for solid cancers found that the side effect profile didn’t differ from controls, with no serious events recorded.10PubMed Central. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer – Section: RESULTS
A larger retrospective study covering patients on various cancer treatments, including chemotherapy, immunotherapy, and radiation, found that about 31% experienced vaccine side effects, which is comparable to the roughly 27% rate reported in the general population. The type of treatment didn’t predict who got side effects, and neither did the timing of the vaccine relative to treatment.11PubMed Central. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study – Section: Results
Boosters Make a Real Difference
Given the weaker initial vaccine response, booster doses are especially important for cancer patients. A large U.S. study found that among people with cancer, booster vaccination reduced the COVID hospitalization rate meaningfully, with vaccine effectiveness around 29% for monovalent boosters and about 30% for bivalent boosters in preventing hospitalization. The protection was significant for patients with lung, breast, and urinary tract cancers, and for those on chemo, immunotherapy, or corticosteroids.12JAMA Oncology. COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer – Section: Results
A population-based study found stronger numbers for a third dose: vaccine effectiveness against COVID-related death in cancer patients reached about 95%, with effectiveness against hospitalization at about 81%. However, patients who had been diagnosed within the past year, had lymphoma, or were on recent systemic therapy saw lower effectiveness.13PubMed Central. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study – Section: RESULTS Another large study confirmed that a third dose was consistently linked to lower risks of breakthrough infection, emergency visits, severe outcomes, and death across both solid and blood cancers.14JAMA Oncology. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer – Section: Results
Paxlovid and Cancer Drugs Don’t Always Mix
If you test positive for COVID while on chemotherapy, the antiviral Paxlovid (nirmatrelvir/ritonavir) might seem like an obvious treatment. But this is one area where cancer patients face a unique problem. Paxlovid contains ritonavir, which strongly blocks a liver enzyme called CYP3A4. Many cancer drugs, including widely used ones like taxanes, vinca alkaloids, and tyrosine kinase inhibitors, are processed by that same enzyme. Taking both together can cause the cancer drug to accumulate in your body to potentially toxic levels.15PubMed Central. Oral antivirals for COVID-19 among patients with cancer – Section: Discussion
The severity of these interactions varies depending on which cancer drug you’re taking. Some interactions can be managed by temporarily pausing or adjusting the cancer medication, while others may make Paxlovid effectively off-limits.16PubMed Central. Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer – Section: CONCLUSIONS There’s also concern that when cancer patients already have altered drug metabolism because of COVID itself, adding Paxlovid to the mix could make things worse.17Scientific Reports. Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 – Section: Discussion This doesn’t mean you can’t take antivirals. It means your oncologist and infectious disease specialist need to review your specific medications before prescribing one. Do not skip this conversation.
What About Monoclonal Antibodies?
Earlier in the pandemic, monoclonal antibodies were a lifeline for immunocompromised patients who couldn’t generate a strong vaccine response. One combination, tixagevimab/cilgavimab (sold as Evusheld), showed solid effectiveness in reducing COVID infection, hospitalization, and death among immunosuppressed people, with effectiveness against COVID-specific death reaching about 92%.18PubMed. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients Unfortunately, viral evolution has outpaced these treatments. Monoclonal antibodies that were effective against earlier strains have proven ineffective against more recent Omicron subvariants, and the FDA has revoked emergency use authorizations for several of these products.19PubMed. Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations – Section: RESULTS This leaves vaccination and antivirals (when compatible) as the main preventive and treatment tools.
When Symptoms Overlap
Chemotherapy causes its own set of symptoms that can look a lot like COVID: fever, fatigue, cough, and shortness of breath. The overlap creates a genuine diagnostic challenge. Febrile neutropenia, a well-known chemo complication involving fever and dangerously low white blood cell counts, needs rapid treatment with antibiotics. COVID-19 also causes fever and can trigger secondary infections. Distinguishing between the two matters because the treatments are different and delays can be dangerous either way.20PubMed Central. The challenges in colorectal cancer management during COVID-19 epidemic – Section: Abstract
Medical organizations have emphasized that any cancer patient presenting with fever during a pandemic needs screening for COVID infection alongside standard evaluations for febrile neutropenia.21PubMed Central. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper If you develop a fever on chemo, don’t try to figure out the cause yourself. Contact your care team immediately, because both possibilities require urgent attention.
Restarting Chemo After a Positive Test
One of the most anxiety-inducing questions for patients is how long they need to wait before resuming treatment after catching COVID. Delaying chemotherapy creates its own risk: the cancer keeps growing. During pandemic surges in Iran, researchers documented significantly increased treatment delays, particularly during the first wave.22BMC Public Health. Chemotherapy delays among cancer patients in Iran during COVID-19 pandemic – Section: RESULTS
The good news from more recent research is that restarting treatment relatively soon after testing negative appears to be safe. A retrospective study found that resuming anti-tumor therapy early after a negative SARS-CoV-2 test did not increase treatment-related side effects or reinfection rates.23PubMed Central. When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study – Section: CONCLUSION Some centers have used a more conservative protocol, requiring at least 20 days since symptom onset, fever resolution for at least 72 hours without medication, a negative test, and no signs of active pneumonia on imaging.24Japanese Journal of Clinical Oncology. COVID-19 in patients receiving treatment at an outpatient chemotherapy unit – Section: Patients and methods Practices vary by institution, so the timeline should be worked out with your oncologist based on your specific situation, the severity of your COVID course, and your blood counts.
Long COVID and Cancer
Cancer patients who recover from acute COVID-19 face a substantial risk of persistent symptoms. In one study of 312 cancer patients, about 60% reported long COVID symptoms, with a median duration of seven months and some lasting over a year. The most common complaints were fatigue, sleep disturbances, muscle pain, and gastrointestinal symptoms. Women reported persistent symptoms more often than men.25PubMed Central. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period – Section: Results Many of these symptoms overlap with chemotherapy side effects, making it difficult for patients and clinicians to tease apart what is causing what. This is an area where research is still catching up, and patients dealing with prolonged fatigue or cognitive fog after COVID should raise the issue with their oncology team rather than assuming it’s just from their cancer treatment.
The Mental Health Toll
Living with cancer is already psychologically grueling. Adding a pandemic on top created a perfect storm for mental health problems. Studies found that roughly half of cancer patients on active treatment experienced significant psychological distress during the pandemic.26PubMed Central. Psychological impacts of COVID-19 pandemic in cancer patients on active treatment – Section: Results In one survey, anxiety symptoms were detected in about 62% and depression in about 70% of cancer patients sampled, with isolation being a significant driver of anxiety.27PubMed Central. Impact of the COVID-19 Pandemic on Oncology Patients’ Mental Health and Treatment Plans – Section: Results A meta-analysis confirmed that the pandemic added an extra burden on top of baseline rates of depression and anxiety that cancer patients already experience.28Translational Psychiatry. Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic – Section: Discussion
Fear of catching a deadly infection while immunosuppressed, worry about delayed treatments, and enforced isolation from family during hospital stays all contributed. These effects haven’t fully resolved. If you’re a cancer patient or caregiver and mental health feels like an afterthought in your treatment plan, it’s worth explicitly asking your oncology team about psychosocial support services.
Protecting the Household
One of the simplest and most effective things cancer patients can do is ensure that the people around them are vaccinated. The American Society of Clinical Oncology guidelines specifically note that vaccination of household contacts enhances protection for patients with cancer.29PubMed Central. Vaccination of Adults With Cancer: ASCO Guideline – Section: RECOMMENDATIONS This is especially important given the weaker vaccine response in chemo patients themselves. A “cocoon” strategy, where everyone in close regular contact stays up to date on vaccinations, reduces the chance of the virus reaching the vulnerable person in the first place.
Surgical masks remain safe for chemo patients. A study specifically investigating whether wearing a mask during infusion sessions posed any respiratory risk found that while masks caused minor, measurable changes in carbon dioxide and oxygen levels, these changes were clinically insignificant and stayed within normal ranges.30Scientific Reports. Wearing a surgical mask during chemotherapy session is safe – Section: Conclusion For patients who feel uneasy about masking for hours during an infusion, that finding should offer some reassurance.
Telehealth Gaps That Haven’t Closed
The pandemic accelerated the use of telehealth in oncology, which has real benefits for immunosuppressed patients who’d rather not sit in crowded waiting rooms. But the shift hasn’t been equitable. Black and uninsured cancer patients were significantly less likely to use telemedicine than White and well-insured patients. Patients living in rural areas and low-income neighborhoods were also underrepresented in telehealth use.31PubMed Central. Sociodemographic Inequities in Telemedicine Use Among US Patients Initiating Treatment in Community Cancer Centers During the Ongoing COVID-19 Pandemic, 2020-2022 – Section: RESULTS
The divide extended to the type of telehealth used. Older adults, rural residents, and patients of color were more likely to rely on phone calls rather than video visits, which limits the quality of the clinical encounter.32PubMed Central. Telehealth in cancer care during COVID-19: disparities by age, race/ethnicity, and residential status – Section: RESULTS Financially distressed patients with cancer also had fewer telehealth visits as neighborhood deprivation increased.33PubMed Central. Determinants of telemedicine adoption among financially distressed patients with cancer during the COVID-19 pandemic: insights from a nationwide study – Section: RESULTS These gaps mean that the patients most vulnerable to COVID complications may also be the ones least likely to access remote care that could help them avoid infection exposure.
COVID During Childhood Cancer Treatment
Parents of children on chemotherapy face their own set of worries. Evidence from a tertiary hospital study of pediatric cancer patients who caught COVID while on treatment found that most children had either no symptoms or mild illness. Febrile neutropenia occurred in about a third of cases, and disease severity was linked to both neutropenia and hospital-acquired infections. The overall mortality rate was very low, with the one death in the cohort being unrelated to COVID, and about 97% of children were discharged alive.34Oxford Academic. Chemotherapy Outcomes Among Pediatric Cancer Patients with Active COVID-19 Infection in a Tertiary Hospital – Section: Abstract While this is only one study from a single center, it aligns with the broader pattern seen in pediatric COVID data: children generally fare better, even when immunocompromised, though febrile neutropenia remains a serious concern that requires immediate medical attention regardless of the cause.